Cabaletta Bio Inc CABA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
11.26UNCH (UNCH)
Volume
15,781
Close
11.26quote price arrow down-0.96 (-7.86%)
Volume
843,707
52 week range
9.02 - 26.35
Loading...
  • Open12.33
  • Day High12.57
  • Day Low11.17
  • Prev Close12.22
  • 52 Week High26.35
  • 52 Week High Date02/08/24
  • 52 Week Low9.02
  • 52 Week Low Date05/30/23

Key Stats

  • Market Cap527.022M
  • Shares Out46.80M
  • 10 Day Average Volume1.93M
  • Dividend-
  • Dividend Yield-
  • Beta2.52
  • YTD % Change-50.4

KEY STATS

  • Open12.33
  • Day High12.57
  • Day Low11.17
  • Prev Close12.22
  • 52 Week High26.35
  • 52 Week High Date02/08/24
  • 52 Week Low9.02
  • 52 Week Low Date05/30/23
  • Market Cap527.022M
  • Shares Out46.80M
  • 10 Day Average Volume1.93M
  • Dividend-
  • Dividend Yield-
  • Beta2.52
  • YTD % Change-50.4

RATIOS/PROFITABILITY

  • EPS (TTM)-1.65
  • P/E (TTM)-6.81
  • Fwd P/E (NTM)-5.90
  • EBITDA (TTM)-73.234M
  • ROE (TTM)-39.72%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cabaletta Bio Inc

 

Profile

MORE
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T...
Steven Nichtberger M.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Anup Marda
Chief Financial Officer
Michael Gerard
General Counsel, Secretary
Address
2929 Arch Street, Suite 600
Philadelphia, PA
19104
United States

Top Peers

SYMBOLLASTCHG%CHG
AVTE
Aerovate Therapeutics Inc
19.83-1.73-8.02%
OLMA
Olema Pharmaceuticals Inc
9.32-0.52-5.28%
PHAT
Phathom Pharmaceuticals Inc
9.53-0.56-5.60%
IGMS
IGM Biosciences Inc
9.34-0.78-7.71%
LYEL
Lyell Immunopharma Inc
2.46-0.22-8.21%